With new names making headlines all year, its easy to lose track of what you can actually get. A mid-2026 snapshot of the FDA-approved toxins available now, and the much-hyped ones still under review.
As of mid-2026, six botulinum toxin type A products are FDA-approved for aesthetic use in the US: Botox, Dysport, Xeomin, Jeuveau, Daxxify, and Letybo. Several buzzy candidates, including the liquid toxin Relfydess and the fast-acting type-E TrenibotE, remain under FDA review and are not yet available, despite frequent headlines.
2026 has been a noisy year for neurotoxins, with new products and trial data arriving almost monthly.
Heres a clear, mid-year snapshot of what is actually available versus what is still ahead.
By mid-2026, the US market includes six FDA-approved botulinum toxin type A products for aesthetic use: Botox (onabotulinumtoxinA), Dysport (abobotulinumtoxinA), Xeomin (incobotulinumtoxinA), Jeuveau (prabotulinumtoxinA), Daxxify (daxibotulinumtoxinA), and Letybo (letibotulinumtoxinA), the newest approved entrant. They share the same basic mechanism but differ in formulation, approved uses, and practical characteristics, and importantly, their dosing units are not interchangeable between products.
Several heavily covered candidates remain investigational in the US. Relfydess (relabotulinumtoxinA), a ready-to-use liquid toxin approved in 20-plus markets abroad, is under FDA review with no announced US launch date. TrenibotE (trenibotulinumtoxinE), a fast-acting, short-duration type-E toxin, is also under FDA review. Other names, such as the next-generation corabotase, remain in clinical development and are not approved anywhere for sale. Frequent headlines about these products describe trials or foreign approvals, not US availability.
For consumers, the gap between headline and availability is the key takeaway. A toxin you read about may be approved abroad, in trials, or simply hyped, yet not legally available in the US. Because dosing units differ between products, comparisons by units are also misleading. The practical move is to confirm that any toxin offered is FDA-approved for the intended use, and to rely on a providers experience rather than novelty alone.
Watch the FDA decisions on Relfydess and TrenibotE, which would expand US options, and the progress of next-generation candidates like corabotase. Each approval, if it comes, would genuinely change the menu. Until then, treat international approvals and trial data as context. For patients, the steady guidance is to choose an FDA-approved product appropriate for the goal and a qualified injector, rather than chasing a not-yet-available name.